A Federal Trade Commission (FTC) case against insulin price gouging has come to a screeching halt after two Democratic commissioners were fired by President Donald Trump.
On March 31, the FTC stayed its suit against pharmacy middle managers, called pharmacy benefit managers (PBMs). Government investigations, including one by the FTC, have pointed to PBMs, as behind at least part of the high prices.
